FCMV
VRDN icon

Foresite Capital Management VI’s Viridian Therapeutics VRDN Stock Holding History

Foresite Capital Management VI’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,974
Closed -$27.6K – 19
2025
Q2 		$27.6K Hold
1,974
– – 0.02% 20
2025
Q1 		$26.6K Hold
1,974
– – 0.01% 14
2024
Q4 		$37.8K Buy
+1,974
New +$42.9K 0.02% 14

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Foresite Capital Management VI's VRDN Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Viridian Therapeutics (VRDN) in Q3 2025, closing a stake of 1,974 shares — an estimated $27.6K sold.

Foresite Capital Management VI first reported a position in VRDN in Q4 2024 and held it in 3 quarters. The position peaked at $37.8K in Q4 2024. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Viridian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 1,974 Viridian Therapeutics shares in Q3 2025, an estimated $27.6K.
  • Foresite Capital Management VI first reported a position in Viridian Therapeutics in Q4 2024 and held it in 3 quarters.
  • Foresite Capital Management VI's Viridian Therapeutics position peaked at $37.8K in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.